Form 6-K PolyPid Ltd. For: Jul 29

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of: July 2026 (Report No. 3)

 

Commission File Number: 001-38428

 

PolyPid Ltd.

(Translation of registrant’s name into English)

 

18 Hasivim Street

Petach Tikva 495376, Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F      ☐ Form 40-F

 

 

 

CONTENTS

 

Attached hereto and incorporated herein is PolyPid Ltd.’s (the “Registrant”) press release issued on July 29, 2026, titled “PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀.”

 

The first, third and fourth paragraphs and the section titled “Forward-looking Statements” in the press release are incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658, File No. 333-281863, File No. 333-284376 and File No. 333-289034)  and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703, File No. 333-280662 and File No. 333-289570) filed  with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

 

 

EXHIBIT INDEX

 

Exhibit No.
99.1		Press Release issued by PolyPid Ltd. on July 29, 2026, titled “PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100.”

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	POLYPID LTD.
Date: July 29, 2026	By:	/s/ Dikla Czaczkes Akselbrad
		Name	: Dikla Czaczkes Akselbrad
		Title:	Chief Executive Officer

 

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE ISSUED BY POLYPID LTD. ON JULY 29, 2026, TITLED "POLYPID ANNOUNCES FDA ACCEPTANCE OF NDA WITH PRIORITY REVIEW FOR D-PLEX100."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• stackArmor Receives FedRAMP High Authorization for The Armory
• WMD Law Marks 25 Years of Scholarship Program Driving Legal Careers
• Pakistan Assumes Chairmanship of the Shanghai Cooperation Organisation